 "food, demand, sales, FMCG, consumer, customers, coronavirus")
Homegrown pharma major Cipla Ltd announced the launch of its generic version of remdesivir, which has been authorised for emergency use in treatment of Covid-19 patients by the USFDA, under its brand name Cipremi.
The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of Covid-19 patients.
Remdesivir is the only USFDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed Covid-19 infection.
In May, Gilead Sciences Inc extended a voluntary non-exclusive license to Cipla to manufacture and market generic version
